For those with stage 4 PCa there is hope:

Subject: Treatment with ProstaSol
Please find some feedback from our tumor board members as to further treatment options for your present situation. I also have included some comments into your own message text here below in blue print for convenience.

In your present situation, we would recommend the following treatment measures:

1. Aeskulap Oral Medication Protocol

1. ProstaSol: 3×1 tablet per day
2. IMUSAN: 3×1 capsule per day
3. Curcumin combi extra forte: 3×1 capsule per day
4. Aeskulap-Sitosterol-Mix
5. BioBran: 2×1 Sachet per day
6. Aeskulap-MCP: 3×3 capsules per day

We have provided some information on the recommended oral medications here in the attached PDF-files for your review. Please, contact our Service and Logistics Office for help with any order ([email protected]). Our staff will be glad to assist you. Once you have the medication in hand, we will provide further details as to how to start the protocol and what to measure prior to starting.

1. Aeskulap Infusion Protocol

This treatment is done in blocks of 5 continuous days and repeated as needed from 1 to 4 times per month. For you, we recommend the following regimen:

Day 1: 

450 mg Curcumin in 500 ml 0.9% normal saline solution + 60-90 g buffered Vitamin C in 500 ml 0.9% normal saline solution + 150 mg Q10 in 250 ml 0.9% normal saline solution + 1200 mg Glutathione in 100ml 0.9% normal saline solution + 100 mg Thymus extract (directly i.v. through the same line)

Day 2: 

500 mg Artesunate dissolved in 100 ml 8.4% sodium bicarbonate and diluted in 500 ml 0.9% normal saline solution + 900 microgram Selenium and 1 vial Aeskulap Vitamin B complex (without B1) in 250 ml 0.9% normal saline solution

Day 3: 

1ml Hematoxylin/DMSO mix in either 500 ml 0.9% normal saline solution or 5% Glucose solution + 1200 mg Glutathione in 100ml 0.9% normal saline solution + 100 mg Thymus extract (directly i.v. through the same line); increase the hematoxylin/DMSO dose to 1.25 ml for the second infusion, to 1.5 ml for the third infusion and to 1.75 ml for the following infusions

Day 4: 

500 mg Artesunate dissolved in 100 ml 8.4% sodium bicarbonate and diluted in 500 ml 0.9% normal saline solution + 900 microgram Selenium and 1 vial Aeskulap Vitamin B complex (without B1) in 250 ml 0.9% normal saline solution

Day 5: 

450 mg Curcumin in 500 ml 0.9% normal saline solution + 60-90 g buffered Vitamin C in 500 ml 0.9% normal

saline solution + 150 mg Q10 in 250 ml 0.9% normal saline solution + 1200 mg Glutathione in 100ml 0.9

normal saline solution + 100 mg Thymus extract (directly i.v. through the same line)

Note: These medications are made by our compounding pharmacy. They cannot be prescribed in Australia, however, we have patients who have organized infusions with our medication through their local doctor.

1. Tumor Vaccination with “Designer Peptides” 

Our cancer vaccination treatment program is utilizing “Next Generation DNA Sequencing” and treatment with a “designer peptide mix” containing information about the mutations of your metastatic cancer cells translated into an antigen mix used for the actual vaccination (please see our attached general information sheet for reference). This program is being administered in close cooperation with CEGAT, Germany’s most prominent genetics institute (www.cegat.de). If you decide to enroll in our vaccination protocol, then we would need paraffin blocks with your tumor tissue from the pathology department for the tumor DNA extraction. You would also have to send us a fresh blood withdrawal for the DNA sequencing of your normal cells. Full genome analysis would allow to identify somatic mutations in the DNA of your tumor cells providing more detailed diagnostic information that can support treatment decisions.

1. Adoptive Immunotherapy with NK-Cell Culture

Natural killer (NK) cells are innate lymphocytes that play a pivotal role in host immunity against cancer. In cancer patients, this primary defense system has somehow failed to eliminate the initial cancer cell and allowed clinical significant cancer to develop. Insufficient numbers of NK cells and functional disturbances of these cells caused by the growing tumor likely play an important role in the cancer process. In stage 4 patients, we see significantly less active NK cells, often with impaired function. Therefore, the adoptive transfer of cultured NK cells to a cancer patient is an intriguing new concept in cancer therapy that has already shown encouraging results in several clinical studies. Our NK cell treatment program is administered in close cooperation with University of Tuebingen in Germany. Our partner there is Professor Rupert Handgretinger, Germany’s most prominent oncologists (https://www.uni-tuebingen.de/fakultaeten/medizinische-fakultaet/forschungsschwerpunkte/immunology-and-oncology/handgretinger-rupert.html). For this program, you would have to travel to Germany for the blood withdrawal to collect your NK cells for the culturing process. Three weeks later, when enough NK cells have been cultured (usually a couple of billions!), treatment is done by intravenous infusion of these cultured cells.

1. TACE (transarterial chemoembolization) and tumor ablation

These treatments use local chemoembolization via selective angiography (arterial catheter is advanced to the primary tumor or its metastases) followed by a ablation treatment utilizing microwave-, radiofrequency- or laser technology to create heat within the tumor until the cancer cells are destroyed). Of course, without reviewing your latest imaging diagnostic (PSMA PET CT), we are unable to decide whether you indeed are a candidate for this treatment option. However, if you were, then this treatment could provide significant benefit to you. This treatment would be organized at our partner institute, the University of Frankfurt, in close cooperation with Professor Dr. Thomas Vogl (http://www.leading-medicine-guide.com/en/Specialist-Radiology-Frankfurt-Prof-Vogl), who is Europe’s foremost expert in regional chemotherapy, TACE and tumor ablation techniques.

We hope this treatment proposal and the attached information is helpful to you. Please, feel free to contact me with questions. Perhaps a SKYPE consult would be the best to discuss details and logistics of our suggested treatment plan.

Ben Pfeifer, M.D.,Ph.D.
Professor & Director of Research
Aeskulap-International, Lucerne, Switzerland
Phone: +41 41 417 4448 Fax: +41 41 417 4449

______________________________________________